Table 3.
Adjusted hospitalization costs based on MCS strategy by diagnosis
| Cardiomyopathy
| ||||||
|---|---|---|---|---|---|---|
| Total Hospitalization Costs | N (%) | Adjusted Costs ¥ | p-value § | |||
|
|
||||||
| All patients | 1318 | (100%) | $484,744 | ($340,184 - | $689,643) | - |
| Type of MCS | ||||||
| None | 899 | (68.2%) | $397,726 | ($304,486 - | $535,694) | <0.001 |
| VAD | 373 | (28.3%) | $699,220 | ($560,056 - | $977,340) | Ref. |
| ECMO | 46 | (3.5%) | $679,291 | ($526,415 - | $857,366) | 0.256 |
|
| ||||||
| Pre-Transplant Costs | N (%) | Adjusted Costs ¥ | p-value | |||
|
|
||||||
| All patients | 1318 | (100%) | $168,202 | ($80,675 - | $328,112) | - |
| Type of MCS | ||||||
| None | 899 | (68.2%) | $110,368 | ($60,051 - | $196,123) | <0.001 |
| VAD | 373 | (28.3%) | $401,943 | ($284,902 - | $575,938) | Ref. |
| ECMO | 46 | (3.5%) | $196,768 | ($125,764 - | $305,497) | <0.001 |
|
| ||||||
| Post-Transplant Costs | N (%) | Adjusted Costs ¥ | p-value | |||
|
|
||||||
| All patients | 1318 | (100%) | $293,246 | ($239,532 - | $385,874) | - |
| Type of MCS | ||||||
| None | 899 | (68.2%) | $282,340 | ($231,569 - | $364,733) | <0.001 |
| VAD | 373 | (28.3%) | $308,141 | ($256,566 - | $416,031) | Ref. |
| ECMO | 46 | (3.5%) | $476,258 | ($366,415 - | $610,768) | <0.001 |
|
| ||||||
| Congenital heart disease
| ||||||
| Total Hospitalization Costs | N (%) | Adjusted Costs ¥ | p-value § | |||
|
|
||||||
| All patients | 1363 | (100%) | $557,435 | ($415,292 - | $837,336) | - |
| Type of MCS | ||||||
| None | 1193 | (87.5%) | $519,921 | ($399,902 - | $757,307) | <0.001 |
| VAD | 85 | (6.2%) | $1,000,163 | ($693,263 - | $1,472,652) | Ref. |
| ECMO | 85 | (6.2%) | $898,993 | ($646,604 - | $1,273,851) | 0.111 |
|
| ||||||
| Pre-Transplant Costs | N (%) | Adjusted Costs ¥ | p-value | |||
|
|
||||||
| All patients | 1363 | (100%) | $175,097 | ($87,460 - | $307,907) | - |
| Type of MCS | ||||||
| None | 1193 | (87.5%) | $155,599 | ($80,176 - | $264,372) | <0.001 |
| VAD | 85 | (6.2%) | $561,807 | ($391,079 - | $903,231) | Ref. |
| ECMO | 85 | (6.2%) | $315,634 | ($195,343 - | $511,169) | <0.001 |
|
| ||||||
| Post-Transplant Costs | N (%) | Adjusted Costs ¥ | p-value | |||
|
|
||||||
| All patients | 1363 | (100%) | $373,063 | ($296,035 - | $517,102) | - |
| Type of MCS | ||||||
| None | 1193 | (87.5%) | $364,171 | ($291,514 - | $488,149) | 0.001 |
| VAD | 85 | (6.2%) | $404,650 | ($332,049 - | $591,514) | Ref. |
| ECMO | 85 | (6.2%) | $579,937 | ($466,061 - | $821,927) | <0.001 |
§
P-values from the Wilcoxon rank sum test comparing VAD vs. no support and VAD vs. ECMO
¥
Cost model adjusted for the following variables: Patient age, diagnosis, race, blood type, hospital, ECMO (pre- or post-transplant), VAD, ventilator support, inotropic support, length of ICU stay post-transplant, dialysis post-transplant, and transplant year.